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Reproductive medicine
The clinical services in reproductive medicine were among the 
first of their kind in South Africa (SA). In the mid-1970s a 
medical endocrinologist was appointed to develop gynaecological 
endocrinology and a service laboratory was established in 
collaboration with the Departments of Chemical Pathology and 
Medicine to support the clinical input. In 2006 a Reproductive 
Medicine Unit was established, comprising the gynaecological 
endocrine clinic and laboratory, infertility services, menopause care, 
an endocrine antenatal clinic, a recurrent miscarriage clinic, family-
planning services and attendant subspecialist surgery. We discuss 
the resulting clinical research in contraception and interception, the 
polycystic ovary syndrome and infertility in Africa. 
Contraception and interception 
Fertility regulation has always been an interest. In 1995 the UK 
Medical Research Council and the UK Department for International 
Development (DFID) jointly funded a programme of research within 
the Contraceptive Development Network (CDN) for developing 
new contraceptive methods in a network of centres in Cape Town, 
Edinburgh, Shanghai, Hong Kong, and later Sagamu, Nigeria. 
Initially, surveys accessed the opinions of contraceptive users about 
potential new methods. Subsequently, we studied the potential of 
hormonal male contraception and non-oestrogen-containing female 
contraception.1-6
Our contraceptive research unfortunately demonstrates that the 
knowledge of both healthcare providers and users is often inadequate. 
A survey of educational programmes is under way; one aim is to 
understand why the intra-uterine device (IUD) is under-utilised and 
patients and healthcare providers have limited knowledge of this 
method.7 These studies contribute to our services and we hope to see 
considerable improvement in the next decade.   
Benign gynaecological disorders
Our unit has focused on polycystic ovary syndrome (PCOS). We 
have a database comprised of the details of almost 1 500 women who 
presented with PCOS to our clinical services; information includes 
metabolic and endocrinological profiles currently being prepared for 
publication. 
Family studies have demonstrated a higher prevalence of PCOS 
in the sisters (45.4%) and daughters (55.6%) of women with PCOS 
compared with the general population. An adverse lipid profile was 
also found in mothers and sisters of probands with PCOS.   
We are collaborating with the University of Oxford on the 
genetics of women with benign gynaecological disorders, including 
PCOS and uterine fibroids. As a result, two publications reviewing 
possible genetic mutations in women with uterine fibroids have been 
produced. This research has considerable significance, given the high 
prevalence of uterine fibroids in African women. It is interesting that 
the genetic mutations of our patient population are similar to those 
of Europe, despite the higher prevalence and earlier presentation in 
Africa.8
Infertility 
We have explored infertility in Africa from the angle of the 
psychological and social experience of infertility, and the inter-
relationship of this experience with infertility-related healthcare. 
Qualitative research found that infertility was a highly distressing and 
often stigmatising experience for women.9 For many, the experience 
of involuntary childlessness was shaped by emotional distress, marital 
instability with fear of divorce or infidelity, ridicule from members 
of the family and community, verbal and, at times, physical abuse 
from the partner, and considerable social pressure to have a child. 
In contrast, some women felt well supported by their husbands and 
social network, and appeared to cope better with their inability to 
conceive. 
Our research and publications from other African countries 
show that women carry the main burden of infertility, but men 
too are affected. Men frequently experienced sadness, pain and 
feelings of emptiness, and some expressed anger and frustration.10 
The distress described by women and men in qualitative studies 
proves quantifiable.11 Comparison with studies using the same 
research instrument suggested a greater width and depth of distress 
among infertile women in SA compared with infertile women in 
western industrialised countries.12 Similarly, male partners of infertile 
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couples in our community had higher levels of distress on all sub-
scales compared with male partners of pregnant women;13 therefore 
infertility profoundly influences the lives of SA women and men and 
is frequently associated with distressing psychological and social 
consequences. 
This reality of infertility is shaped by the generally high value 
placed on children in African countries. Qualitative social science 
research from sub-Saharan Africa describes these roles in rich detail: 
children complete marriage, confer social status, protect rights of 
property and inheritance, assist with labour, satisfy emotional needs, 
offer social security in old age, and provide continuity by maintaining 
family lineage. Closely linked to the value of children are the motives 
for men and women to desire parenthood. Infertile couples attending 
Groote Schuur Hospital (GSH) endorsed most motives of the 
Parenthood-Motivation-List, an instrument developed to measure 
parenthood motives.14 In Western industrialised countries, men and 
women desired children predominantly for personal happiness and 
fulfilment, and the conjugal relationship;15 therefore, it appears that 
in addition to happiness and parenthood, other factors from culture, 
society, continuity and heritage influence the desire to have children 
in our setting.   
The burden of disease has become an increasingly important 
topic in health science research and resource allocation in the past 2 
decades. Existing generic instruments are not sensitive to infertility, 
especially in African and other developing countries where people’s 
lives are often profoundly affected and disease-specific instruments 
are, by and large, lacking. To address this challenge our unit is 
developing instruments to contribute to our understanding of the 
needs of women with infertility.
Gynaecological oncology
The Gynaecology Oncology Unit was one of the first subspecialties 
established and is an important source of research. Over the past 15 
years it has focused on cervical cancer prevention in low-resource 
settings. The Khayelitsha cervical cancer screening project (KCCSP) 
was established in 1995. Cervical cancer is now relatively rare in 
women living in developed countries, where secondary prevention 
using the Pap smear, combined with colposcopy and the removal of 
precancerous lesions, has been very successful. In contrast, no low-
resource country has managed to initiate or sustain cervical cancer 
prevention strategies, due to a lack of resources. Our project evaluated 
alternative protocols for cervical cancer prevention, specifically 
to evaluate different screening tests compared to cytology, and to 
measure the impact on the reduction in cervical cancer precursors. 
In each of the initial 2 projects, just under 3 000 previously 
unscreened women aged 35 - 65 years were screened with 4 screening 
tests: (i) cytology; (ii) screening for high-risk types of human 
papillomavirus (HPV) (DNA testing); (iii) visual inspection with 
(5%) acetic acid (VIA) to visualise aceto-whitening, an indication 
of an underlying cervical cancer precursor; and (iv) cervicography, 
in which the cervix was photographed after VIA using a specially 
adapted camera. Women with abnormal tests were referred for 
colposcopy and histological assessment in phase 1. In phase 2, a 
random sample of women with negative results for all 4 tests was 
referred for colposcopy to eliminate verification bias.
Cervicography had low sensitivity and specificity; it was considered 
of value for VIA quality control but not as a primary screening test. 
Data indicated that screening with VIA and HPV DNA testing 
could identify 1 in 4 or 1 in 5 screen-positive women, necessitating 
either referral or treatment.16 Data also indicated that both VIA 
and HPV DNA testing could lead to considerable overtreatment of 
screen-positive women. To interrogate whether that mattered, we 
established a randomised controlled trial to evaluate screening safety, 
acceptability and efficacy. A total of 6 555 women aged 35 - 65 years 
were randomised to 1 of 3 groups: (i) treatment if HPV-positive 
(treatment was performed by primary care nurses at primary care 
level using cryotherapy to ablate the transformation zone of the 
cervix – a procedure performed on site without the need for local 
anaesthetic), (ii) treatment if VIA-positive, or (iii) delayed treatment 
for 6 months, regardless of the screening test result. 
This study showed that HPV DNA testing combined with 
cryotherapy resulted in a 75% reduction in cervical cancer precursors 
compared with the control/delayed treatment group. However, VIA 
was associated with only a one-third reduction in cervical cancer. 
Evaluated longitudinally, the performance of VIA, compared to HPV 
DNA testing, was significantly inferior over a 36-month period of 
follow-up.17,18 
This work has been duplicated in several developing countries on 
the Indian sub-continent, and in Latin America and Africa. While 
HPV DNA testing is superior to VIA, there is no test that allows 
point-of-care testing and treatment, or HPV test that is affordable, 
although several are in development. Linking screening to treatment 
in one visit is desirable to overcome the many logistical barriers 
women in poor countries must overcome to access healthcare. While 
inferior, VIA allows a screening infrastructure to be created in low-
resource settings, which in turn will be available once improved 
quality tests are developed.
While secondary prevention of cervical cancer through screening 
has dominated prevention efforts in the last century, primary 
prevention with vaccines against high-risk HPV (aetiologically 
associated with cervical cancer) is highly effective in preventing 
HPV-related disease. Available vaccines include the bivalent vaccine 
(against HPV 16, 18; Cervarix, GlaxoSmithKline Biologicals, 
Rixensart, Belgium) and quadrivalent vaccine (against HPV 6, 11, 16, 
18; Gardasil, Merck and Co., Inc, West Point, Pennsylvania, USA). 
The KCCSP has completed a randomised double blinded phase 1/11 
trial of the safety and immunogenicity of the bivalent vaccine in HIV-
positive women aged 18 - 25 years. The first such trial in the world, 
it has shown that the vaccine is as safe and immunogenic as it is in 
HIV-negative women.
The project is recruiting women to an HPV therapeutic vaccine 
trial. The vaccine, developed by Inovio, is designed to promote 
regression of dysplastic lesions caused by infection of the cervix 
with HPV types 16 and 18. This novel approach would allow 
circumvention of the complex processes required by secondary 
prevention with screening tests.
Urogynaecology
Urogynaecology focuses on managing women with pelvic floor 
dysfunction. In treatment, the boundaries between the specialties 
are blurred and input is often required from gynaecology, urology 
and colorectal surgery. A progressive step in treating women with 
urinary incontinence was the establishment of the multi-disciplinary 
female continence clinic at GSH. This clinic, with equal input 
from gynaecology, urology and physiotherapy was one of the first 
of its kind in SA. It is an ideal platform for research into female 
urinary incontinence, focusing mainly on developing innovative 
management strategies. 
The overactive bladder (OAB) is an additional area of interest, 
with a prevalence of 15 - 20% in the general population. Standard 
management of OAB includes anticholinergic drug therapy, 
bladder retraining and pelvic floor muscle exercises. A significant 
proportion of women have a suboptimal response to treatment; an 
Australian study showed that after 10 years of attending a specialist 
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incontinence clinic, only 30% of women showed improvement.19 A 
small retrospective study of 100 patients attending our clinic over 
the past 12 years showed similar results; 62% of the women claimed 
that their condition was unimproved or worse. This has prompted 
research into novel treatment strategies in women with OAB in our 
department over the past 15 years. 
In Europe and the USA, treatment with sacral nerve stimulation, 
by implantation of a neuromodulator in the region of the sacral 
nerve roots, demonstrated remarkable improvements in urinary 
urgency and incontinence. As this device is costly and requires an 
infrastructure for insertion and technical support, there was an unmet 
need for a simplified device. We studied a simplified nerve stimulator 
implanted in the abdominal wall, with a neuromodulating effect 
via the pudendal nerve. This device was associated with significant 
improvements in women with refractory urinary incontinence.20 
A randomised controlled trial in the USA by Emmons et al.21 
demonstrated significant improvements in continence outcomes 
in women treated with bladder-specific acupuncture compared 
with relaxation-point acupuncture. This prompted us to investigate 
acupuncture for treating urge urinary incontinence. Our prospective 
cohort study on women with refractory OAB demonstrated significant 
improvement in quality-of-life scores following bladder-specific 
acupuncture.22 Unfortunately, it is difficult to ascertain the extent of 
the placebo effect with acupuncture trials; despite this, we believe that 
it is an inexpensive and safe treatment alternative in these women. 
Stress incontinence surgery has evolved rapidly over the past 
decade with the development of minimally invasive slings inserted 
under the mid-urethra; this has replaced major surgical interventions 
such as the colposuspension. The next-generation device, the mini-
sling, requires a single 1 cm vaginal incision; this can be done as 
an outpatient procedure under local anaesthesia. Our department 
has published a meta-analysis of these devices, and found a lack of 
good level-one evidence on their efficacy.23 In collaboration with 
the University of Stellenbosch, we are undertaking a randomised 
controlled trial comparing the Needleless single incision sling to the 
standard transoburator tape. 
Our unit also has a keen interest in maternal injuries sustained 
at childbirth. We performed a case control study comparing the 
outcomes of third and fourth degree perineal tears in HIV-positive 
and -negative women. HIV-positive women had poorer functional 
faecal continence outcomes,24 suggesting that HIV may have an 
impact on anal sphincter muscle function. A larger clinical study is 
required to substantiate our findings and a laboratory-based study on 
the impact of HIV on muscle function may reveal interesting data. 
Conclusion
The development of a strong subspecialty programme in gynaecology 
has improved the care of women accessing our services. The resultant 
research has contributed to changes in therapeutic approaches and 
service delivery and should ultimately impact on the heavy burden of 
disease caused by reproductive ill-health among women.
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